1887
Volume 2015, Issue 1
  • ISSN: 2305-7823
  • E-ISSN:

ملخص

In the Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy (PALLAS) study, dronedarone use was associated with an excess risk of stroke, cardiovascular death and hospitalizations. However, an increased level in the serum digoxin level was observed in the dronedarone arm, as it is a potent inhibitor of the P-glycoprotein transport system. The PALLAS subanalysis suggests that digoxin-dronedarone interaction was responsible for the higher arrhythmic death rate observed in the trial. These data are consistent with several other studies that demonstrate the potential hazard of the use of digoxin in heart failure and/or atrial fibrillation. One must consider other safer alternatives before prescribing digoxin in atrial fibrillation patients.

Loading

جارٍ تحميل قياسات المقالة...

/content/journals/10.5339/gcsp.2015.4
٢٠١٥-٠٣-٠١
٢٠٢٤-٠٧-١٣
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2015/1/gcsp.2015.4.html?itemId=/content/journals/10.5339/gcsp.2015.4&mimeType=html&fmt=ahah

References

  1. Zimetbaum P. Antiarrhythmic Drug Therapy for Atrial Fibrillation. Circulation 2012; 125:2:381389. doi:10.1161/CIRCULATIONAHA.111.019927 .
    [Google الباحث العلمي]
  2. Hohnloser S, Crijns H, van Eickels M, Gaudin C, Page R, Torp-Pedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. Rev Port Cardiol. 2009; 28::345347.
    [Google الباحث العلمي]
  3. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggrefe M, Budaj A, Chen S-A, Ching CK, Commerford P, Dans A, Davy J-M, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim K-H, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse H-F, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu J-R, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH. Dronedarone in High-Risk Permanent Atrial Fibrillation. N Eng J Med. 2011; 365:24:22682276. doi:10.1056/NEJMoa1109867..
    [Google الباحث العلمي]
  4. Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ. Interaction Between Digoxin and Dronedarone in the PALLAS Trial. 2014.
    [Google الباحث العلمي]
  5. Singh BN, Connolly SJ, Crijns HJGM, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357::987999.
    [Google الباحث العلمي]
  6. Køber L, Torp-Pedersen C, McMurray JJV, Gøtzsche O, Lévy S, Crijns H, Amlie J, Carlsen J. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358::26782687.
    [Google الباحث العلمي]
  7. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2009; 54::10891095.
    [Google الباحث العلمي]
  8. Withering W, An account of the Foxglove and some of its medical uses: with practical remarks on dropsy, and other diseases. Birmingham: G.G.J and J. Robinson, Paternoster-Row, London 1785.
  9. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith K, Van Voorhees L, Gourley LA, Jolly MK. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Eng J Med. 1993; 329:1:17. doi:10.1056/NEJM199307013290101..
    [Google الباحث العلمي]
  10. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993; 22:4:955962.
    [Google الباحث العلمي]
  11. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336:8:525533. doi:10.1056/NEJM199702203360801..
    [Google الباحث العلمي]
  12. Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013; 6::525533.
    [Google الباحث العلمي]
  13. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J, Morales G, Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC, Jondeau G, Natale A, Roy D, Smyth S, Moliterno DJ, Elayi CS. Increased mortality among patients taking digoxin–analysis from the AFFIRM study. Eur Heart J [Internet]. 2013; 34::14811488. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23186806 .
    [Google الباحث العلمي]
/content/journals/10.5339/gcsp.2015.4
Loading
/content/journals/10.5339/gcsp.2015.4
Loading

جارٍ تحميل البيانات والوسائط...

  • نوع المستند: Research Article
هذه الخانة مطلوبة
يُرجى إدخال عنوان بريد إلكتروني صالح
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error